ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly and Company will pay ImmuNext $40 million as part of a research pact focused on an autoimmune disease drug target. The companies have not identified the target but note that most autoimmune therapies dampen the immune system’s response, whereas they want to develop an antibody that can reprogram the immune system. Under the deal, which could be worth $565 million for ImmuNext if products reach the market, Lilly gets a license on a target related to metabolism of white blood cells.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter